Addex Amends ATM Agreement with H.C. Wainwright for $3.3M Offering
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 11 2025
0mins
Source: Newsfilter
- Financing Plan Revision: Addex Therapeutics announced an amendment to its ATM Agreement with H.C. Wainwright & Co., allowing for the sale of ADSs with an aggregate offering price of up to $3.3 million, aimed at enhancing funding flexibility to support the development of neurological disorders.
- Sales Commission Structure: Under the new agreement, Addex will pay H.C. Wainwright a 3% sales commission, a structure that incentivizes the agent to actively promote the sale of ADSs, potentially accelerating capital raising efforts.
- Market Sales Flexibility: Addex retains the flexibility to determine the timing and quantity of ADS sales based on market conditions and company needs, which will help the company optimize its financing strategy in an uncertain market environment.
- Risk Management Measures: The agreement includes customary indemnification and contribution rights, ensuring that Addex can effectively manage potential legal risks during the sales process, thereby protecting the company's long-term interests.
Analyst Views on ADXN
About ADXN
Addex Therapeutics Ltd is a Switzerland-based clinical-stage pharmaceutical company. The Company focuses on development and commercialization of orally available small molecule drugs known as allosteric modulators for neurological disorders. The Company’s clinical programs pipeline include dipraglurant (mGlu5 NAM), which is Phase 2a placebo-controlled clinical trial for Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID, and ADX71149 (mGlu2 positive allosteric modulator or PAM), which is being developed in collaboration by its partner Janssen Pharmaceuticals, Inc to treat schizophrenia and anxious depression. It also is advancing several preclinical programs, including GABABPAM for pain, overactive bladder and other disorders, mGlu7 NAM for post-traumatic stress disorder, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
